ADVERTISEMENT
Abstracts
P046
Selinexor for the Treatment of Patients with Relapsed or Refractory Multiple Myeloma (RRMM)
Introduction:
Multiple Myeloma (MM) cells show resistance to standard therapies due to overexpression of the transport protein, Exportin 1. Selinexor is a novel drug that targets the Exportin 1 protein on these cells. Clinical trials are underway to maximize the effectiveness and tolerability of Selinexor.
Methods:
A comprehensive search was done, and data showing the efficacy and safety of Selinexor in RRMM was collected using PubMed, Google Scholar, and clincialtrials.gov.
Results:
Results from the clinical trials STORM, BOSTON, and STOMP were included. STORM trial, including Part l and Part ll, showed a progression-free survival (PFS) of 4.7 and 3.7 months, a median duration of response (mDoR) of 6.2 and 4.4 months, an overall survival (OS) of 7.3 and 8.4 months and a clinical benefit ratio (CBR) of 31.6% and 39.3% respectively.
The STOMP trial is still active, with multiple arms and limited data available. The SKd arm (Selinexor, carfilzomib, and dexamethasone) showed an ORR of 78%, mPFS of 3.7 months, and mOS of 22.4 months. The SDd arm (Selinexor, daratumumab, and dexamethasone) showed an ORR of 69%, PFS of 12.5 months, and CBR of 81%. The SPd arm (Selinexor, pomalidomide, and dexamethasone) showed an ORR of 50%, PFS of 10.4 months, CBR of 68%. The SRd arm (Selinexor, lenalidomide, dexamethasone) showed an ORR of 81% and a CBR of 80%. The SVd (Selinexor, bortezomib and dexamethasone) arm showed an ORR of 63%, PFS of 9 months, mDoR of 13 months, and a CBR of 80%.
Multiple Myeloma (MM) cells show resistance to standard therapies due to overexpression of the transport protein, Exportin 1. Selinexor is a novel drug that targets the Exportin 1 protein on these cells. Clinical trials are underway to maximize the effectiveness and tolerability of Selinexor.
Methods:
A comprehensive search was done, and data showing the efficacy and safety of Selinexor in RRMM was collected using PubMed, Google Scholar, and clincialtrials.gov.
Results:
Results from the clinical trials STORM, BOSTON, and STOMP were included. STORM trial, including Part l and Part ll, showed a progression-free survival (PFS) of 4.7 and 3.7 months, a median duration of response (mDoR) of 6.2 and 4.4 months, an overall survival (OS) of 7.3 and 8.4 months and a clinical benefit ratio (CBR) of 31.6% and 39.3% respectively.
The STOMP trial is still active, with multiple arms and limited data available. The SKd arm (Selinexor, carfilzomib, and dexamethasone) showed an ORR of 78%, mPFS of 3.7 months, and mOS of 22.4 months. The SDd arm (Selinexor, daratumumab, and dexamethasone) showed an ORR of 69%, PFS of 12.5 months, and CBR of 81%. The SPd arm (Selinexor, pomalidomide, and dexamethasone) showed an ORR of 50%, PFS of 10.4 months, CBR of 68%. The SRd arm (Selinexor, lenalidomide, dexamethasone) showed an ORR of 81% and a CBR of 80%. The SVd (Selinexor, bortezomib and dexamethasone) arm showed an ORR of 63%, PFS of 9 months, mDoR of 13 months, and a CBR of 80%.
Publisher
John Wiley & Sons; Hoboken, USA
Source Journal
American Journal of Hematology
2022 Wiley Periodicals LLC.
